公开(公告)号：US20180326084A1

公开(公告)日：2018-11-15

申请号：US15742818

申请日：2016-07-08

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Kirstine JACOBSEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Henrik Jørn DITZEL ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K47/6803 ,  A61K39/001102 ,  A61K45/06 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2863 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.